ArticleRedox biology2026
Spermidine attenuates monocrotaline-induced pulmonary arterial hypertension with HADHA-associated improvements in fatty acid oxidation and mitochondrial redox homeostasis.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic reprogramming, impaired mitochondrial quality control, and mitochondrial redox imbalance are increasingly recognized as central drivers of pulmonary arterial hypertension (PAH). Spermidine (SPD) has been reported to exert cardiovascular protective effects; however, its effects on endothelial metabolism and redox homeostasis in PAH remain incompletely characterized. HADHA, the α-subunit of mitochondrial trifunctional protein, participates in long-chain fatty acid β-oxidation (FAO) and provides a potential link between fatty acid utilization, mitochondrial respiration, mitophagy-related quality control, and redox homeostasis. Here, using integrated metabolomics, lipidomics, and molecular biology approaches in monocrotaline (MCT)-induced PAH rats and palmitic acid-stimulated pulmonary microvascular endothelial cells (PMVECs), we examined the contribution of HADHA to the effects of SPD on endothelial FAO and mitochondrial redox homeostasis. SPD treatment markedly attenuated pulmonary hypertension and vascular remodeling, accompanied by reduced inflammatory activation and endothelial injury. Metabolomic and lipidomic profiling indicated that SPD partially corrected pathological lipid-metabolic remodeling, including phosphatidylethanolamine-associated lipid alterations, and improved FAO-related mitochondrial function under lipotoxic stress. SPD reduced lipid accumulation and lipotoxic mitochondrial injury, inhibited PLIN2-vimentin-associated endothelial-to-mesenchymal transition (EndMT) marker changes, and increased PINK1/Parkin-related mitophagy markers together with TOM20/LC3B/LAMP2 colocalization, consistent with improved mitophagy-related mitochondrial quality control. Molecular dynamics simulation, cellular thermal shift assay, and microscale thermophoresis supported SPD-HADHA binding and SPD-associated HADHA stabilization. Importantly, HADHA knockdown markedly attenuated several effects of SPD on FAO-related function, mitochondrial redox balance, and lipotoxic phenotypes in PMVECs. These findings suggest that HADHA may contribute to the effects of SPD on fatty acid oxidation, redox homeostasis, and endothelial protection in PAH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.